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Abstract
Parkinson’s disease (PD), the second most common progressive neurodegenerative
disorder, was long believed to be a non-genetic sporadic origin syndrome. The identifi‐
cation of distinct genetic loci responsible for rare Mendelian forms of PD has represent‐
ed a revolutionary breakthrough, allowing to discover novel mechanisms underlying this
debilitating  still  incurable  condition.  Along with  single-nucleotide  polymorphisms
(SNPs), other kinds of DNA molecular defects have emerged as significant disease-causing
mutations, including large chromosomic structural rearrangements and copy number
variations (CNVs). Due to their size variability and to the different sensitivity and
resolution of detection methodologies, CNVs constitute a particular challenge in genetic
studies and the pathogenetic or susceptibility impact of specific CNVs on PD is currently
under debate. In this chapter, we will review the current literature and bioinformatic data
describing the involvement of CNVs on PD pathobiology. We will discuss the recently
highlighted role of PARK2 heterozygous CNVs, the possible common founder effects of
PD gene rearrangements and the importance to map genetic breakpoints. We will also
add a summary about the current available molecular methods and bioinformatics web
resources to detect and interpret CNVs. Assessing the global genome-wide burden of
large CNVs and elucidating the role of de novo rare structural variants on PD may reveal
new candidate genes and consequently ameliorate diagnosis and counselling of mutations
carriers.
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1. Introduction
Parkinson’s disease (PD) is a progressive debilitating movement disorder and constitutes the
second most common neurologic disease after Alzheimer’s disease, affecting approximately 1%
of the population older than 65 years of age [1].
Clinically, most patients present resting tremor, bradykinesia, stiffness of movement and
postural instability. These major symptoms derive from the profound and selective loss of
dopaminergic neurons of substantia nigra pars compacta (SNc), although SNc seems to become
involved later in the middle stage of the disease [1]. The neuropathological hallmarks of PD
are round eosinophilic intracytoplasmic inclusions termed Lewy bodies (LBs) and dystro‐
phic neurites (Lewy neurites) present in surviving neurons [1], both composed of alpha-
synuclein aggregates. In more advanced stages, patients can also develop a range of non-motor
symptoms, including rapid eye movement, sleep behaviour disorder, constipation, depres‐
sion and cognitive decline. Although drugs such a levodopa (L-DOPA) or surgical interven‐
tion (deep brain stimulation) can alleviate the motor symptoms, they do not halt disease
progression and are not effective against the non-motor aspects of the disease [2].
PD is primarily a sporadic multifactorial disorder, resulting from an elaborate interplay of
numerous elements: genes, susceptibility alleles, environmental exposures, gene-environ‐
ment interactions and their overall impact on developing and aging brain. Important in‐
sights have been provided during the last years through studying the genetics, epidemiology
and neuropathology of PD, together with the development of experimental in vivo and in vitro
models. A prominent role of common underlying pathways, such as mitochondrial dysfunc‐
tions [3], oxidative stress [4] and impairment of the ubiquitin/proteasome system (UPS)
system [5], is now supported by accumulating genetic studies, which demonstrate that PD-
associated genes directly or indirectly impinge on mitochondrial integrity, reactive oxygen
species production and protein clearance.
In this review chapter, we will introduce the genetics of PD and then we will focus on copy
number variations (CNVs), a form of DNA structural rearrangements, which are currently
attracting researchers’ interest for their role in PD pathobiology.
2. PD: a genetic overview
PD was long believed to be a prototypical non-genetic disorder. In the last 15 years, howev‐
er, the identification of distinct genetic loci responsible for rare monogenic Mendelian forms
and the discovery of numerous risk factors have revolutionized this view and have provid‐
ed novel clues to understand the molecular pathogenesis of this still incurable condition [1].
The Mendelian monogenic forms of PD are well-established and collectively account for
about 30% of the familial and 3–5% of the sporadic cases [6]. These rare forms are caused by
mutations in specific genes, which are inherited from parents in either a dominant or reces‐
sive way.
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In the autosomal-dominant inheritance, one mutated allele of the gene is sufficient to cause
the disease [6]. The SNCA (alpha-synuclein) gene, localized in the PARK1 locus, was the first
to be associated to this pattern of transmission and was identified in an Italian American family
with more than 60 affected individuals distributed on five generations [7]. Among family
members, the disease was caused by the Ala53Thr (A53T) missense mutation, which induces
a conformational change in the protein chain and facilitates alpha-synuclein aggregation.
Additional disease-causing mutations in SNCA are currently known, including genetic
variations in the coding regions (Ala30Pro, Glu46Lys), single-nucleotide substitution in 3′ UTR
and dose-dependent genomic multiplications (duplications or triplications) [8–10] that will be
discussed in the next sections. A second gene clearly associated to the dominant PD inheri‐
tance is LRRK2 (locus PARK8), which encodes a large multi-domain protein called leucine-
rich repeat kinase 2. LRRK2 harbours several genetic variants recognized as pathogenic, some
of which represent the most frequent causes of Mendelian and sporadic PD identified so far
(i.e. Gly2019Ser and mutations altering codon Arg1441). The precise physiological function of
LRRK2 is unknown; however, it is probably implicated in different cellular functions such as
neurite outgrowth, cytoskeletal maintenance, vesicle trafficking and autophagic protein
degradation [11].
Some monogenic forms of PD are inherited with the autosomal recessive pattern, and
frequently, symptoms have an early onset. In these disorders, mutations in both alleles
(either homozygous or compound heterozygous) cause the pathological phenotype [6].
Mutations in three genes cause the recessive typical form:
• PARKIN (locus PARK2), the most commonly mutated gene in the juvenile Parkinsonism,
responsible of 50% of cases;
• PINK1 (locus PARK6), which is present with a frequency variable from 1 to 9% depending
on the ethnic background [12];
• DJ1 (locus PARK7), which represents the less common cause (~1%) [1, 13].
These three genes will be discussed in the next sections.
The recessive cases of Parkinsonism can clinically manifest also in an atypical form, mean‐
ing that patients have clinical features of PD, neuronal loss in the SNc and additional cell
degeneration in other regions of the nervous system, such as in the striatum. The genes
currently identified as responsible of this forms of Parkinsonism are the following:
• ATP13A2 (locus PARK9), whose mutations are associated with the Kufor–Rakeb syn‐
drome, a form of recessively levodopa-responsive inherited atypical Parkinsonism [14]. This
gene belongs to the P-type superfamily of ATPases that transport inorganic cations and
other substrates across cell membranes [15];
• PLA2G6 (phospholipase A2 group VI), localized in the locus PARK14, which has been recently
associated to a particular Parkinsonian phenotype consisting of levodopa-responsive
dystonia, pyramidal signs and cognitive/psychiatric features with onset in early adult‐
hood [16];
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• FBXO7 (F-box only protein 7) is harboured in the PARK15 locus and responsible of the
Parkinsonian-Pyramidal Disease (PPD), an autosomal recessive neurodegenerative disease
with juvenile onset and additional pyramidal signs [17]. FBXO7 is a components of modular
E3 ubiquitin protein ligases called SCFs (SKP1, cullin, F-box proteins), which function in
phosphorylation-dependent ubiquitination.
Despite the existence of rare monogenic forms, it is now clear that PD is a genetically hetero‐
geneous and most likely complex disorder. The complexity of PD is underlined by the notion
that we are currently aware of dozens of more or less convincing loci, genes and risk factors
linked to the different inherited or sporadic forms. For the sake of completeness, we men‐
tion here just some of them: PARK3, GBA, UCHL1, PARK10, GIGYF2, PARK12, HTRA2,
PARK16, DNAJ, HLA-DR, GAK-DGKQ, SYNJ1, GBAP1 [18–20]. This list is progressively
extending thanks to the evidences revealed by linkage mapping analysis, genome-wide
association studies (GWAS) and high-throughput genomic biotechnologies, such as next
generation sequencing and array technologies [18, 21].
However, while the detection and interpretation of some kind of DNA molecular alterations,
as single-nucleotide polymorphisms (SNPs), are relatively simple, CNVs genotyping is
technically more challenging, partially due to the quantitative rather than the qualitative
nature of the assay. These kinds of DNA molecular defects, therefore, are in general under-
represented in genetic studies. In the next paragraphs, we will introduce CNVs and then we
will focus on what is currently known about their pathogenic or susceptibility impact on PD
pathobiology.
3. CNVs: origin, classification and clinical relevance
The genomic sequence along human chromosomes is constantly changing, and this process
enables humans to evolve and adapt. The scientific community have long been aware of genetic
variation at either size extreme (i.e. cytogenetically recognizable elements and SNPs).
However, about 10 years ago, scientists began to recognize abundant variations of an
intermediate size class known as structural variations. Within this class, CNVs, which involves
unbalanced rearrangements that increase or decrease the DNA content, represent the largest
component by far. Currently, the size of CNVs is defined as larger than 50 bp [22] and can be
limited to a single gene or include a contiguous set of genes. These structural variants
encompass more polymorphic base pairs than SNPs and finally result in an altered DNA
diploid status (i.e. gain or loss of genomic region).
DNA structural changes and CNVs originate when specific architectural genomic elements
are present that render DNA regions very susceptible to rearrangements. These latter can be
classified as recurrent or non-recurrent events, depending on whether the same rearrange‐
ment is identified in unrelated individuals [23].
Three major mechanisms for the generation of recurrent and non-recurrent CNVs have been
proposed. The most common cause of recurrent genomic rearrangements is the non-allelic
homologous recombination (NAHR), which occurs during both mitosis and meiosis be‐
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tween two DNA blocks of high homology, like the region-specific low-copy repeats sequen‐
ces (LCRs). Specifically, CNVs generate when tracts of directly oriented LCRs recombine by
unequal crossing-over leading to both deletion and duplication of the genomic fragment [23,
24] (Figure 1). LCRs with different orientations can recombine to produce NAHR-mediated
inversions or more complex genomic rearrangements.
Figure 1. NAHR generates CNVs when genomic segments with high sequence similarity (direct LCRs, green arrows)
recombine. This recombination can generate a duplication of the similar locus (yellow arrow) on one chromosome,
while removing the copy from the other.
Non-recurrent CNVs can mainly result from non-homologous end joining (NHEJ) mecha‐
nism. NHEJ is the major cellular mechanism for double-strand break (DSB) repair. Upon DSB,
NHEJ reconnects chromosome ends, very often editing them before ligation and leaving an
information scar (i.e. random nucleotides added at the site of the breakage to facilitate the
strands’ alignment and ligation) [25] (Figure 2). NHEJ is more often associated with dele‐
tions and chromosomal translocations. However, complicated DNA intermediates have been
proposed as origin mechanisms for duplications as well [26].
Figure 2. DBS in DNA sequence recruit NHEJ associated proteins to repair and ligate DNA strands together. First, end-
repair protein replaces lost nucleotides on the double-strand break and DNA ligase associates broken DNA fragments
together. If fragments from different chromosomes ligate together, duplications or deletions of sequence can occur.
The third mechanism proposed to trigger non-recurrent genomic rearrangements is fork
stalling and template switching (FoSTeS) [27]. FoSTeS occurs when the DNA replication
machinery pauses, the lagging strand dissociates from the polymerase holoenzyme and the
template is switched with another region of the genome that is usually in physical proximity
to the original replication fork. Replication continues based on a wrong template until the
original fork is restored. Such template switching may occur several times before the replica‐
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tion process gets back to its original template, resulting in complex rearrangements (Figure
3) [25]. The pausing and stalling of the DNA replication machinery are common at certain
nucleotide motifs and repetitive DNA sequences; however, such events can also occur due to
chemical changes in DNA structure as DNA lesions or DNA alkylization [26]. CNVs generat‐
ed by FoSTeS mainly originate during the S phase of the cell cycle as a consequence of DNA
repair mechanisms. It should be noted that the CNVs created through FoSTeS are difficult to
be distinguished from those generated by micro-homology-mediated breakpoint-induced
repair (MMBIR), a mechanism of end-joining that relies on small-scale homology of DNA
sequence at the ends of DSBs [26].
Figure 3. After the original stalling of the replication fork (dark blue lines), the lagging strand disengages and anneals
to a second fork (green lines), followed by extension of the now ‘primed’ second fork and DNA synthesis. After the
fork disengages, the tethered original fork with its lagging strand (blue and green lines) could invade a third fork (red
lines). Serial replication fork disengaging and lagging strand invasion could occur several times (e.g. FoSTeS × 2,
FoSTeS × 3, etc.) before resumption of replication on the original template.
Challenges in Parkinson's Disease12
CNVs are very common and constitute a prevalent source of genomic variations. These
alterations may account for adaptive or behavioural traits, may have no phenotypic effects or
can underlie diseases [22]. For this reason, determining the clinical significance of CNVs is
very challenging and relies heavily on both frequency information from healthy control
cohorts and databases with previously reported clinically relevant CNVs.
In a clinical setting, CNVs are categorized into five groups (according The American College
of Medical Genetics and Genomics practice guidelines):
• Abnormal or pathogenic (e.g. well-established association with a disease);
• Likely pathogenic;
• VOUS (Variants of uncertain clinical significance – rare or private CNV);
• Likely benign;
• Benign (a polymorphic variant detected in a normal individual without clinical signifi‐
cance).
Specific large CNVs and single-gene dosage alterations have emerged as critical elements for
the development and maintenance of the nervous system [28] and have appeared to contrib‐
ute to hereditable or sporadic neurological diseases, such as neuropathies, epilepsy forms,
autistic syndromes, psychiatric illnesses and also neurodegenerative diseases [23, 29–33]. In
the next paragraphs, we will focus on the current evidences about the recurrence of CNVs in
PD pathobiology.
4. CNVs in PD
4.1. Single-gene CNVs in familiar PD-genes
4.1.1. SNCA
Accumulating evidences show that alpha-synuclein gene (SNCA) copy number gains play a
major role in the disease severity of PARK1. Singleton et al. [34] were the first to describe a
genomic triplication of chromosome 4q21 22 containing the SNCA locus within a large family
with PD autosomal-dominant inheritance pattern and dementia called the Spellman–Muenter
family or Iowa Kindred. The size of the triplication region, confirmed with quantitative
polymerase chain reaction (PCR) and fluorescence in situ hybridization (FISH) methodology,
was over 2.0 Mb.
After the initial description, numerous families with SNCA genomic alterations have been
reported. PD families with members carrying four copies of SNCA gene have been detected in
South Africa, Iran, Japan, Pakistan and Italy [35–40]: in general, triplication generates very high
expression of mRNA and protein and influences the clinical manifestations of PD, causing
severe forms of Parkinsonism similar to dementia with Lewy body. Duplications have been
reported in more numerous families than triplications [33, 38, 41–51]. In some of the patients
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with the same ethnic background (Japan), haplotype analysis revealed their derivation from
common founders [43, 44]. In contrast to triplication carriers, the clinical phenotype of patients
with duplicated SNCA resembles idiopathic PD, mainly with late age at onset, good efficacy
for levodopa therapy, slower disease progression and without early development of demen‐
tia. An interesting familiar case, the Swedish-American family (named the “Lister family”),
presents both duplicated and triplicated SNCA carriers within different branches of the
pedigree (branches J and I), suggesting a primary duplication event followed later by another
one and resulting in the triplication [52, 53]. A similar pedigree, the Ikeuchi family, has both
heterozygote and homozygote duplication from a consanguineous marriage (producing a
pseudo-triplication) [54]. The clinical features of the individual with the SNCA homozygote
duplication showed severe Parkinsonism similar to that of a triplication carrier.
In 2007, Ahn et al. [42] firstly reported two sporadic patients with SNCA duplication from a
large screen of PD patients. The age at onset was 65 and 50 years old for the two patients. Their
clinical course was similar to typical sporadic PD without severe progression or cognitive
decline. Other cases of sporadic PD carrying de novo SNCA duplication were later revealed by
different detection assays [55–59].
The breakpoint of SNCA multiplication is different among families and sporadic patients. The
largest multiplication detected so far is about 41.2 Mb, containing 150 genes and defined a
partial trisomy 4q [55]. The smallest one sizes about 0.2 Mb and was found in a Japanese
family [43]. The size and gene make-up of each multiplicated region does not seem to severely
influence the clinical presentation of the carrier. The single common determining factor that
appears between all patients with SNCA multiplications is the presence of the more than two
copies of the entire gene.
Significant data regard the mosaicism of SNCA rearrangements, indicating the situation in
which not all the body cells present the same genetic composition but specific groups of cells
have a different genomic architecture. In this regard, Perandones et al. [60] have reported two
interesting cases. In these patients, the exon dosage test conducted on peripheral blood
revealed no alterations, while FISH analysis conducted on interphase cells from the buccal
cavity (oral mucosa cells) revealed a good percentage of cells with SNCA triplication or
duplication. It should be noted that both patients displayed a Parkinsonian clinical pheno‐
type already described for the SNCA duplication or triplication carriers. Since usually only
DNA from peripheral lymphocytic tissues are examined for SNCA rearrangements, it should
be taken into consideration that the possibility to examine cells from other tissues in order to
detect low-grade mosaicism.
4.1.2. PARK2
Although the SNCA story suggests a gain of function, several early-onset forms of PD have
demonstrated the role of loss of function in the aetiology of the disease. The most common
loss-of-function causes of early-onset PD are mutations in Parkin (or PARK2) gene, one of the
largest known genes of our genome harboured in the long arm of chromosome 6 (6q25.2-q27)
and encoding an E3 ubiquitin ligase. Mutations of PARK2 are particularly frequent in
individuals with evidence of familiar recessive inheritance and account for 50% of the cases
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with juvenile PD. Parkin mutations also explain ~15% of the sporadic cases with onset
before 45 [61, 62] and act as susceptibility alleles for late-onset forms of PD (2% of cases) [63].
The PARK2 gene has a high mutation rate since it is located in the core of FRA6E site, one of
the most mutation-susceptible common fragile site of human genome [25]. For this reason,
more than 200 putative pathogenic mutations have been reported worldwide, affecting
numerous ethnic populations [33, 35, 59, 64–77]. The PARK2 mutation spectrum includes
homozygous or compound heterozygous missense and nonsense point mutations, as well as
several exon rearrangements (both duplications and deletions) involving all 12 exons and the
promoter region. The list of studies focusing on PARK2 CNVs is such high that describing
them one by one is very arduous. Overall, Parkin CNVs mutations published so far are
summarized in Figure 4 and are collected in the Parkinson Disease Mutation database (http://
www.molgen.vib-ua.be/PDMutDB), whose the reader is referred for a more complete
overview. Recently, our research group has outlined a complex alternative splicing mecha‐
nism regulating the expression of PARK2 [78–80]. These data suggest the existence of five
additional exons that, however, have never been considered for dosage screening.
Figure 4. Schematic representation of PARK2 genetic structure and currently identified CNVs in PD patients. All the
canonical PARK2 exons are involved in exons rearrangements. Red bars correspond to exons deletions, blue bars to
duplications and yellow bars to triplications. All depicted CNVs can be found at the Parkinson Disease Mutation data‐
base (http://www.molgen.vib-ua.be/PDMutDB).
CNV rearrangements involving PARK2 exons accounts for 50–60% of all pathogenic anoma‐
lies, rendering gene-dosage assays essential in Parkin mutational screening [81]. However, the
hot-spot nature of this gene makes its quantitative analysis a particular challenge, and several
issues need to be pointed out in this regard.
First of all, the determination of mutational phase of the rearrangements, meaning the
assessment that amplified or deleted exons are really contiguous. Kim et al. [81] have showed
that phase determination is a prerequisite for PARK2 molecular diagnosis: by phase determi‐
nation, several patients with apparent contiguous multi-exon deletions were re-diagnosed as
compound heterozygotes. Simple gene-dosage assays seem to be not sufficient to determine
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the phase of rearrangements, and therefore, the true incidence of molecularly confirmed
Parkin-type early-onset PD may be underestimated.
A second important point refers to breakpoint mapping which can be useful to compare exon
rearrangements between patients and families and to study the possible causing event
mechanism [82]. Just few papers have addressed this issue so far, but mostly report rearrange‐
ments into the region between PARK2 exons 2 and 8 [25, 82]. In the majority of mapped cases,
micro-homologies at breakpoint junctions were present, thus supporting NHEJ and FoSTeS/
MMBIR as the major mechanisms responsible for PARK2 genomic rearrangements [25].
Despite these hypotheses, it cannot be excluded that PARK2 CNVs may arise in some minor
ethnic groups from an ancient founder [83]. For example, haplotype analysis in four families
from The Netherlands has showed a common haplotype of 1.2 Mb responsible for exon 7
duplication and a common haplotype of 6.3 Mb responsible for exon 4 deletion [82].
A relevant matter of ongoing debates is the pathogenic role of single-heterozygous PARK2
CNVs. Several studies have sought to address this issue, but the findings published so far are
inconsistent and conflicting. Some reports indicate that CNVs heterozygous mutations in
PARK2 associate with increased PD risk [49, 68], albeit others found no differences for an
association [33, 69]. Not only association studies but also examinations of families have yielded
contradictory results. Heterozygous family members of homozygous carriers have been
described with mild PD signs of late onset [84, 85], whereas another group found no typical
clinical signs of the disease [33]. Very recently, Huttenlocher et al. [86] have genotyped a large
sample of Icelanders, observing that PD patients were more often heterozygous carriers of
CNVs than controls, and confirmed these results by a meta-analysis study. These findings seem
again to suggest that heterozygous carriers of PARK2 CNVs have greater risk of developing
PD than non-carriers.
4.1.3. PINK1
Pathogenic mutations in the PTEN-induced kinase (PINK1) gene are much less common than
PARK2 mutations with a frequency variable from 1 to 9% depending on the ethnic back‐
ground [12]. The encoded protein is a putative serine/threonine kinase of 581 amino acids
involved in mitochondrial response to cellular and oxidative stress [87].
Homozygous deletions involving different combination of exons 4–8 have been described in
both familial and sporadic early-onset cases coming from Japan, Brazil, Sudan and Iran [38,
88–91]. Just in one of them, breakpoint analysis has been performed, revealing a complex
rearrangement combining a large deletion and the insertion of a duplicated sequence from the
neighbouring DDOST gene intron 2 [91]. As suggested by breakpoint analysis, this rearrange‐
ment may result from FoSTeS mechanism. Only one case of a sporadic patient carrying two
different CNVs on PINK1 (compound heterozygous mutations) has been reported until now,
consisting of exon 2 deletion in one allele and exons 2–4 deletion in the other one [38].
The spectrum mutation of PINK1 CNVs is enlarged by the heterozygous cases that, however,
do not explain the recessive inheritance. The largest heterozygous deletion published so far
includes the entire PINK1 gene and spans for 56 kb [92]. This deletion also partly involves two
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neighbouring genes and two highly similar AluJo repeat sequences. It is likely that the deletion
results from an unequal crossing-over between these two sequences. Further heterozygous
deletions involving exons 1, 3–8 and exon 7 have been described in familial or sporadic cases
of early-onset PD [72, 93, 94].
4.1.4. DJ1
The PARK7 locus on chromosome 1p36 was localized by homozygosity mapping in two
consanguineous families from genetically isolated communities in the Netherlands and Italy
[95, 96]. In one of the families, a 14 kb deletion involving the first five of seven exons in the
DJ-1 gene has been identified [95]. Furthermore, three siblings of Iranian origins born from
consanguineous parents and carriers of a homozygous deletion of exon 5 have been descri‐
bed [38].
The product of DJ-1 is a highly conserved multifunctional protein belonging to the pepti‐
dase C56 family [97]. It acts as positive regulator of transcription, redox-sensitive chaperone
and sensor for oxidative stress and apparently protects neurons from ROS-induced apopto‐
sis [98, 99]. Alu repeat elements flank the deleted sequence on both sides, suggesting that
unequal crossing-over is likely at the origin of this rare genomic rearrangement [2].
Further heterozygous CNVs (both deletions and duplication) involving the exons of DJ-1 gene
have been published so far [93, 100–102], although they do not completely explain the recessive
pattern of the PD phenotype.
4.1.5. ATP13A2
ATP13A2 mutations are associated with Kufor–Rakeb syndrome (KRS), a form of recessively
levodopa-responsive inherited atypical Parkinsonism [14]. It encodes a large protein belong‐
ing to the ATPase transmembrane transporters, and recently, it has been identified as a potent
modifier of the toxicity induced by alpha-synuclein [103].
To our knowledge, just one family from Iran with deletion of ATP13A2 has been reported [38].
Specifically, three affected siblings born from consanguineous parents have been described as
carriers of a homozygous deletion of exon 2. All three affected individuals had moderate
mental retardation, aggressive behaviours, visual hallucinations, supranuclear vertical gaze
paresis, slow vertical saccades and dystonia. Cognitive function deteriorated rapidly and all
three affected individuals had dementia by age 10. Further clinical and genetic follow-up of
KRS patients will increase the knowledge on the natural history and clinical features of this
syndrome.
4.2. Rare single-gene CNVs in other PD-genes
4.2.1. TH
The tyrosine hydroxylase (TH) gene encodes a monooxygenase that catalyses the conversion
of L-tyrosine to L-dihydroxyphenylalanine (L-DOPA), which constitutes the rate-limiting step
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in dopamine biosynthesis. Consistent with the essential role of TH in dopamine homeostasis,
missense mutations in TH have been associated with severe Parkinsonism-related pheno‐
types, such as Segawa’s syndrome, L-DOPA-responsive infantile Parkinsonism or L-DOPA-
responsive dystonia (DRD) in recessive form [104].
In 2010, for the first time, Bademci et al. [105] reported a 34 kb deletion of the entire TH gene
in a 54 years-age-at-onset PD patient, presenting no evidence for dystonia, but responsive to
L-DOPA treatment. The deletion was first identified by CNV analysis in a GWAS using SNP
array, then confirmed by multiple quantitative PCR assays and was not found in any of 642
controls.
More recently, Ormazabal et al. [106] reported a DRD patient with a deletion in TH encom‐
passing several exons. A heterozygous exon 12 deletion was first identified by MLPA.
Additional analysis with long range PCR over breakpoints confirmed the deletion encom‐
passing a segment of 716 bp (c.1197 + 25_1391del) including exon 12 and part of exon 13. The
patient also had a heterozygous mutation (c.1 – 70 G > A) at promoter region in another allele.
The promoter mutation was believed to be the underlying cause for DRD phenotype, but
authors recommend the inclusion of structural variant analysis for those patients with clinical
and biochemical features of TH deficiency lacking molecular confirmation by the usual
sequencing techniques.
4.2.2. VPS35
In 2011, two independent groups reported the identification of the same missense mutation
(p.Asp620Asn) in the vacuolar protein sorting 35 (VPS35) gene as a novel disease-causing
mutation in large autosomal-dominant PD pedigrees of Austrian and Swiss origins [107, 108].
After this discovery, Verstraeten et al. [109] performed in-depth sequence and dosage analyses
of VPS35 in an extended LBD patient group comprised of PD, PD with dementia, and dementia
with LBs patients living throughout Flanders. The dosage analyses were performed using
multiplex amplicon quantification, but no CNVs were detected in this patient’s cohort. Despite
these data, it cannot be excluded that CNVs in VPS35 maybe occur in other PD patients groups
and contribute to PD onset. It has very recently demonstrated that specific deletion of VPS35
in dopaminergic neurons of deficient mice resulted in PD-like deficits including loss of
dopaminergic neurons and accumulation of alpha-synuclein [110].
4.2.3. PGRN
The progranulin (PGRN) gene is expressed in a wide variety of tissues including neuronal and
microglial populations of the central nervous system and encodes for an autocrine growth
factor [111]. Its loss-of-function mutations are responsible for ubiquitin-positive frontotempo‐
ral lobar degeneration linked to chromosome 17 (FTLDU-17). A deletion of exons 1–11 of the
PGRN has been reported in a patient with typical PGRN neuropathology, and equally, in his
sister presenting PD [111]. The deletion resulted from a non-homologous recombination event
and was measured by using quantitative multiplex PCR of short fluorescent fragments.
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Although PGRN mutations are certainly not a major cause of PD, these data suggest that PGRN
CNVs may attend to PD mechanisms.
4.2.4. HMOX1
A relevant feature of PD development is the abnormal iron deposition in the SN of PD
patients [112]. The HMOX (Heme oxygenase) protein degrades heme ring to biliverdin, free
ferrous iron and carbon monoxide being the rate-limiting activity in heme catabolism. The
isoform HMOX1 is highly inducible in response to oxidative stress, which is considered a
significant pathway altered in PD conditions. Based on these major findings, Ayuso et al. [112]
analysed exon 3 dosage alterations in the HMOX1 gene in 691 patients suffering from PD
and 766 healthy control individuals. CNVs of the HMOX1 gene were analyzed using a TaqMan
assay, designed to hybridize just within the HMOX1 exon 3. CNV analyses in the whole study
group revealed the occurrence of three patients with PD and six control individuals with a
single copy of the HMOX1 gene. Thus, authors conclude that HMOX1 CNVs exist but they do
not seem to have a major association with PD risk. However, it cannot be excluded the
occurrence of structural alterations in other HMOX1 exons.
4.3. The 22q11.2 deletion
The 22q11.2 deletion syndrome (22qDS), also known as Di George or velocardiofacial
syndrome, is a multi-system disorder caused by a chromosomal microdeletion most com‐
monly involving a 3 Mb segment on the long arm of chromosome 22. Several case reports of
individuals with the hemizygous deletion of chromosome 22q11.2 and some clinical features
of Parkinsonism have suggested that this genetic anomaly may also confer an increased risk
of early-onset PD [113–115]. Some of these cases were reported to be treated with L-DOPA,
while in other case, presynaptic dopamine imaging indicated degeneration of the nigrostria‐
tal dopamine system [113–115]. To investigate the association between 22q11.2 deletions and
PD, Butcher and colleagues [116] assessed the occurrence of a clinical diagnosis of PD in a well-
characterized cohort of adults with 22qDS. They also examined available brain tissue from 3
individuals with 22qDS and an ante-mortem diagnosis of PD. They reported four patients with
the 22q11.2 hemizygous deletion and diagnosed of early-onset PD. Three of them also
displayed typical neuropathological features with prominent LBs and Lewy neurite forma‐
tions on autopsy examination. The authors concluded chromosome 22q11.2 deletions may
represent a novel risk factor for early-onset PD and, with their neuropathological data,
excluded that Parkinsonian clinical features can be due to adverse effects of antipsychotics.
Ogaki and Ross [117] proposed it is not the microdeletion per se that is responsible for the
phenotype, but rather the complete loss of function of a gene at the locus due to the combina‐
tion of the deletion and a mutation on the other allele. Indeed, the chromosome 22q11.2 region
contains some excellent candidate genes, such as COMT, encoding catechol-O-methyltrans‐
ferase that is involved in catecholamine catabolism including dopamine and thus plays a role
in regulating dopamine levels (COMT-inhibitor has been used as a treatment for PD). The
deletion region also contains SEPT5, encoding SEPTIN5 that functionally interacts with
PARK2, and DGCR8 that encodes a subunit of a complex which mediates the biogenesis of
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microRNAs, including miR-185 (also encoded within the chromosome 22q11.2 deletion) which
is predicted to target LRRK2 [117].
Very recently, a 37-year-old early-onset PD patient was found carrying the 22q11.2 deletion
but lacking the more severe features of 22qDS, such as cardiac defect, palatal defect and
hypocalcemia [118]. The deletion was revealed using chromosomal microarray analysis,
suggesting that this genetic test should be considered as part of the evaluation for patients
with early-onset PD and other features associated with 22qDS. Interestingly, very recently,
Perandones et al. [119] reported a case of mosaicism of a patient from an Ashkenazi Jewish
ethnic group with a history of midline defects and PD onset at 46 years. In this patient, FISH
test detected a mosaicism of a 22q deletion in 24% of the analyzed blood cells, highlighting the
relevance of performing individual cell-by-cell analysis, at least until single-cell sequencing
becomes optimized and generally available. The pathogenesis of early-onset PD in patients
with 22qDS remains unknown but, if elucidated, it may contribute to understanding the
aetiology of PD and ultimately to prevention and treatment strategies.
4.4. CNVs involving the mtDNA of PD patients
Mitochondria dysfunction was implicated in the pathogenesis of idiopathic PD. Accumulat‐
ed evidence of mitochondrial DNA (mtDNA) anomalies has been observed in PD patients,
including increased mtDNA deletions/rearrangements in both cerebral area (SN and stria‐
tum) and peripheral tissues (skeletal muscle) [120–122]. The number and variety of mtDNA
deletions/rearrangements seem to be selectively increased in the SN of PD patients com‐
pared to other disorders (multiple system atrophy and dementia with LBs) as well as pa‐
tients with Alzheimer disease and age-matched controls.
More recently, Gui et al. [123] analyzed the copy number of mtDNA using quantitative real-
time PCR in 414 cases with PD and 231 healthy subjects from mainland of China. The level of
mtDNA was significantly decreased in PD patients’ peripheral blood as compared to that of
healthy controls. Furthermore, lower mtDNA copy number was more frequently detected in
the older onset age group than that in the younger group, suggesting mtDNA content might
be an important genetic event in PD progression. In addition, using direct sequencing, they
examined the mutations in the D-loop (the region that controls replication and transcription
of mtDNA) and in the genomic POLG1 gene. The results revealed that 17% of the PD pa‐
tients carried mutations in the D-loop of mtDNA and that patients carrying mutated POLG1
had a significantly lower copy number of mtDNA than those of PD patients without POLG1
alterations, suggesting a role of POLG1 variations for reducing mtDNA copy number in PD.
5. Genome-wide studies to map CNVs in PD
The typical attempts to identify genetic lesions that underlie monogenic forms of disease have
involved the use of linkage mapping analysis in large pedigrees of several affected individu‐
als with known relationships. The application of genome-wide technologies assays now allows
the fast production of high quality, ultra-dense genotypes, producing rapid mapping and
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localization of genomic deletion and duplication. However, there is still no consensus on the
best approach for the detection or analysis of genome-wide CNVs, and very few studies have
been conducted so far.
The first pilot analyses of structural genetic variations in a large cohort PD patients and
neurologically normal controls have been carried out using the genome-wide SNP associa‐
tion study approach [124]. In this study, no new regions associated with PD were identified,
but several deletions and duplications in PARK2 were observed, confirmed by independent
gene dosage experiments. Some months later, Kim et al. [125], tried to investigate CNVs in PD
patients by array-based comparative genomic hybridization (CGH). They observed several
candidate CNVs in many chromosomes, but finally conclude these did not involve any regions
harbouring genes implicated in PD pathogenesis or progression.
In 2011, Pankratz et al. [49] presented the results of the first systematic genome-wide analy‐
sis of CNVs for PD using CNV calling algorithms. The final sample included 816 cases and 856
controls. They replicated the association of PD susceptibility with PARK2 CNVs and also
detected CNVs in two novel genes, DOCK5 and USP32, associated with an increase in risk for
PD at genome-wide significance. However, neither of these novel loci could be validated with
independent molecular tests.
To identify novel CNVs and to evaluate their contribution to the risk of PD, more recently Liu
et al. [126] have conducted a genome-wide scan for CNVs in a case–control dataset (268 PD
cases and 178 controls), focusing on a genetic isolate, the Ashkenazi Jewish population. Using
high-confidence CNVs, this research group examined the global genome wide burden of large
and rare CNVs. Overall, global burden analyses did not reveal significant differences between
cases and controls, but the deletions were found 1.4 times more often in cases. Interestingly, a
total of 81 PD cases carried a rare genic CNV that was absent in controls. Of note, duplica‐
tion of the OVOS2 (ovostatin 2) gene on Chr. 12p11.21 was identified as significant risk factors
for PD. In one PD case, sample was observed a deletion spanning NSF and WNT3 genes, a
region previously identified as “top-hit” in GWAS studies and physically near to MAPT gene.
Other interesting genes include ATXN3, FBXW7, CHCHD3, HSF1, KLC1 and MBD3, which
participates in the disease pathways with known PD genes.
Whole-genome microarray detection was used to identify somatic CNVs in PD patients by
Pamphlett et al. [127], who investigated the existence of candidate brain-situated genetic
variations missing in blood DNA. In this study, a total of 45 CNVs in PD brain samples but in
any control, brains were founded, including genes related to mitochondrial function (BCL2,
IMMP2L), cellular vesicle formation (NRSN1) and apoptosis (BCL2), pathways implicated in
the pathogenesis of PD. Furthermore, additional private rare CNVs observed in PD brains
have been reported. This study shows that specific-brain CNVs can be detected, and raises the
possibility that brain-situated mutations could underlie some cases of PD.
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6. How to detect and analyse CNVs: molecular methods and bioinformatics
web resources
CNVs can be detected and analysed by laboratory methods restricted to certain locations on
chromosomes (locus-specific levels), or targeting the whole genome (genome-wide level). In
the next sections, we will briefly describe the traditional methodologies, the currently available
high-throughput biotechnologies, and the supporting bioinformatics tools to help the
detection, analysis and interpretation of CNVs.
6.1. Locus-specific methods
6.1.1. RFLP—Southern blotting
The most conventional method for detecting structural rearrangements is RFLP—Southern
blot, which relies on DNA digestion with rare-cut enzyme, electrophoresis separation of
digested DNA fragments by pulsed field gel, membranes transfers and hybridization with
appropriate probes [128]. The RFLP—Southern blot method may be a good choice to resolve
large size CNVs and structural variations. However, there are some drawbacks to this
method: 1) the very low resolution; 2) the higher cost per analysis compared to other meth‐
ods; 3) time-consuming and laborious procedures that require more than a week; 4) the need
for purified high molecular weight DNA. For these reason, the RFLP—Southern blot is not so
much used in both clinical and research fields.
6.1.2. Fluorescence in situ hybridization
FISH is an extremely useful method for the detection of chromosomal abnormalities. This
methods relies on the hybridization of fluorescently labelled DNA probes to metaphase
chromosome spreads (resolution 1–3 Mb) or interphase nuclei (50 kb–2 Mb) [128]. The highest
resolution is obtained by fibre-FISH (5–500 kb), where probes are visualized on mechanical‐
ly stretched chromosome fibres, and is currently the preferred method to precisely deter‐
mine the genomic structure of complex CNVs [128]. Nowadays, FISH combined with multiple
probes labelled in different colours (multicolour FISH), is widely used in clinical diagnostics
as a screening tool to confirm the presence of CNVs and other structural variants [128].
However, FISH has several limitations. Locus-specific probes are expensive, and the proce‐
dure is time-consuming and labour intensive. Furthermore, only a limited number of chro‐
mosomal loci can be screened in a single experiment and the identification of an abnormality
is highly dependent on the DNA probe used, specifically on its size and hybridization
localization.
6.1.3. PCR-based approaches
The first PCR-based technique used for targeted CNV analysis was real-time quantitative
PCR (qPCR) that combines “traditional” endpoint PCR with fluorescent detection technolo‐
gies to record the accumulation of amplicons during PCR cycling [128]. Fluorescence moni‐
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toring systems is based on fluorescence probes (e.g. TaqMan, Scorpions, FRET probes) or DNA-
intercalating agents (SYBR green). With the accumulation of target sequences during PCR, the
fluorescence signal increases. Amplicon quantification relies on the observation of the
threshold cycle number (Ct), at which the amount of an amplified target amplicon is directly
related to the amount of starting target. So a higher or lower starting copy number of a genomic
DNA target will respectively result in a significant earlier or later increase in fluorescence, and
thus, in a decreased or increased Ct. The qPCR technique offers great flexibility and adapta‐
bility, and can be carried out in a closed system, thus eliminating the risk of PCR and sam‐
ple contamination and does not require post-processing of PCR products. Therefore, it has
become one of the most popular methods for CNV analysis, especially for validation of results
obtained by microarray tests.
Another widely used PCR-based approach is MLPA (or multiplex ligand probe amplifica‐
tion). MLPA consists of two oligonucleotide hemiprobes, one synthetic and one derived from
the single-stranded M13 bacteriophage [128]. These oligonucleotides hybridize to adjacent
sites of the target sequence. Each hemiprobe is flanked by universal PCR primer sites and one
of the hemiprobes also has a “stuffer” sequence allowing each probe set to have different
fragment lengths. After the hybridization to genomic DNA, the two hybridized hemiprobes
are ligated resulting in a proportional relation between the number of joined primers and the
target copy number. Then, PCR amplification is carried out using a single universal dye-
labelled primerset. The resulting PCR products are separated by capillary gel electrophore‐
sis followed by data analysis to identify CNVs. Since the relative quantity of each of the PCR
products is proportional to the number of copies of the target sequence, results are given as
allele copy numbers as compared to normal controls. MLPA is specifically developed to screen
up to 50 (on average 20–40) independent loci simultaneously, with results typically available
after 1–3 days.
6.2. Genome-wide high-throughput biotechnologies
As anticipated, the above-described traditional methodological approaches bear objective
limits: they are time-consuming and labour-intensive, they require multiple phase steps and
severe equipment costs and above all do not provide a complete genomic overview of
structural imbalances at sufficiently high resolution. The recent development of the aCGH and
next generation sequencing (NGS) biotechnology has dramatically improved and catalysed
the detection and characterization of multiple CNVs, offering high reproducibility, high
resolution and scalability for complete genome-wide mapping of imbalances [129–133].
6.2.1. CGH array
The application of the whole-genome high-resolution aCGH (comparative genomic hybridi‐
zation array) platforms for detecting deletions or duplications has extensively grown. This
biotechnology is now recognized as the first-tier clinical diagnostic test for individuals with
developmental disabilities or congenital anomalies [134]. In addition, several customized high-
density aCGH, suitably designed to focus on specific clinically relevant chromosomal locations
have been developed [133, 135, 136] and aim to obtain an improved resolution. The design‐
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ing of customized aCGH platforms has been already applied to different human diseases
including neuromuscular diseases, cancer, autism, epilepsy, multiple sclerosis, mitochondri‐
al and metabolic disorders [132, 137–143].
The CGH method uses two different fluorescent dyes for the test (unknown or experimental)
and reference DNA samples, which contemporary hybridize on a microarray glass spotted
with millions of probes. By measuring the ratio between the fluorescence signals of the two
dyes and assuming that the reference sample has a normal diploid, the CNVs can be detect‐
ed as either the gain or loss of signal in the test sample.
6.2.2. Next generation sequencing
In the last few years, the NGS technology is becoming more frequently used in various fields
of life science. The NGS is a high-throughput technology that can output million or billion
short reads from the shotgun sequencing, and thus provides high resolution mapping of
genomic regions. The huge amount of data can be utilized for de novo assembly, SNPs calling,
structural variations and for the detection of CNVs with high resolution. Recently, a variety
of algorithm suitably projected to analyse CNVs has been proposed [144–147], and scientists
are still studying to find out the best one. The application of next-generation sequencing
platforms to PD genetic studies promises to improve resolution and reveal new clues to better
understand its molecular causes.
6.3. Online web resources
The collection of CNVs into web databases has provided an essential tool in interpreting results
for diagnostic laboratories and in helping researchers. Public available repositories are The
Figure 5. Representative view of the tracks data for CNVs loaded into the Human Genome Browser (https://genome-
euro.ucsc.edu/index.html) database. The figure represents SNCA genetic structure, harboured in chromosome 4. Data
deposited in the ISCA, DECIPHER, ClinVar and DGV databases are gathered here and displayed as red bars for dele‐
tions, blue bars for duplications and brown or orange bars for more complex rearrangements.
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Database of Genomic Variants (DGV—http://dgv.tcag.ca/dgv/app/home), The International
Standard for Cytogenomic Arrays (ISCA—http://www.clinicalgenome.org), The database of
Chromosomal Imbalance and Phenotype in Human using Ensembl Resources (DECIPHER—
http://decipher.sanger.ac.uk), and the NCBI Database of Genomic Structural Variations
(dbVAR—http://www.ncbi.nlm.nih.gov/dbvar).
CNVs deposited in these databases are currently loaded into the Human Genome Browser
(http://genome-euro.ucsc.edu/index.html) as searchable tracks (Figure 5). All together, these
databases are helpful in reporting genomic reports updated information on CNVs frequen‐
cies in unaffected controls and are classified in VOUS, benign, pathogenic, likely benign or
likely pathogenic.
7. Conclusive remarks
Several evidences suggest an extensive and complex genetic action of CNVs on PD etiopatho‐
genesis. Thus far, unfortunately, only a small portion of the genetic variance has been
identified; the remaining substantial components remain unknown. Assessing the global
genome-wide burden of large CNVs and elucidating the role of de novo rare structural variants
on PD may reveal new candidate genes, explain a portion of the “missing heritability” (for
example, new susceptibility or causative factors that overall converge on PD syndrome) and
consequently ameliorate diagnosis and counselling of mutations carriers. The forthcoming
new era of genomics data promises to increase resolution and uncover new interesting
perspectives.
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